Phase I Safety and Tolerability Study of Cediranib (RECENTIN™, AZD2171) in Combination with chemo in First Line Lung Cancer Patients
Study identifier:D8480C00054
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase I, Multi-Centre, Open-Label, Dose Selection Study to Assess the Safety and Tolerability of Cediranib (RECENTIN™, AZD2171) in Combination with Etoposide and Cisplatin (EP) as First Line Therapy for Lung Cancer Patients with Extensive Stage or Metastatic Disease for Whom EP Would be a Standard Therapy
Medical condition
lung cancer
Phase
Phase 1
Healthy volunteers
No
Study drug
AZD2171, Etoposide, Cisplatin
Sex
All
Actual Enrollment
62
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Feb 2008
Primary Completion Date: 01 Aug 2009
Study Completion Date: 01 Feb 2012
Study design
Allocation: Non-randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 | Drug: AZD2171 Oral Other Name: Recentin™ |
| Active Comparator: 2 Etoposide + Cisplatin | Drug: Etoposide Intravenous Other Name: Etopophos® Drug: Cisplatin Intravenous Other Name: Platinol |
Contacts
Investigators
Principal Investigator
John Heymach
MD Anderson Cancer Center
